APPLICATION
ANDA210826
TYPE
ANDA
ORIGINAL APPROVAL
2023-01-06
LATEST ACTION
2023-01-06
ROUTE
ORAL
DOSAGE FORM
CAPSULE, EXTENDED RELEASE
MARKETING STATUS
Discontinued
Products
LEVOMILNACIPRAN HYDROCHLORIDEDiscontinued
LEVOMILNACIPRAN HYDROCHLORIDE EQ 80MG BASE · CAPSULE, EXTENDED RELEASE · ORAL
LEVOMILNACIPRAN HYDROCHLORIDEDiscontinued
LEVOMILNACIPRAN HYDROCHLORIDE EQ 20MG BASE · CAPSULE, EXTENDED RELEASE · ORAL
LEVOMILNACIPRAN HYDROCHLORIDEDiscontinued
LEVOMILNACIPRAN HYDROCHLORIDE EQ 120MG BASE · CAPSULE, EXTENDED RELEASE · ORAL
LEVOMILNACIPRAN HYDROCHLORIDEDiscontinued
LEVOMILNACIPRAN HYDROCHLORIDE EQ 40MG BASE · CAPSULE, EXTENDED RELEASE · ORAL
Approval history
2023-01-06UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.